Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model

by Joseph C. McCarthy, MS, Mark Aronovitz, MS, Jennifer J. DuPont, PhD, Timothy D. Calamaras, PhD, Iris Z. Jaffe, MD, PhD, Robert M. Blanton, MD
Published 2017-06-01